A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel
group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day to placebo in
the treatment of patients with relapsing multiple myeloma who received one previous therapy.

Patients will receive study treatment (masitinib/placebo) with the standard therapy
(bortezomib and dexamethazone).

Inclusion Criteria:

1. Patient with confirmed multiple myeloma requiring systemic therapy. A

2. Patient with multiple myeloma relapsing according to the International uniform
response criteria for multiple myeloma (IMWG 2009/ revised Bladé criteria) to one
previous line of treatment

3. Patient with measurable progressive disease

Exclusion Criteria:

1. Patient with peripheral neuropathy Grade >2

2. Patient with hypersensitivity to bortezomib, boron or dexamethasone

3. Patient whose disease progressed during or within 60 days of bortezomib treatment or
of any other Multiple Myeloma therapy

4. Patient who received bortezomib within 6 months of randomization to this study

5. Past discontinuation of bortezomib due to associated grade 3 or higher adverse event

6. Patient with contra-indication to high dose of steroids (including ongoing active
infection, use of live vaccines, virosis such as hepatitis, herpes, varicella, herpes
zoster)